ModPath Chat - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

ModPath Chat — Health & Fitness
ModPath Chat

ModPath Chat is the official podcast of Modern Pathology, the journal of the US and Canadian Academy of Pathology (USCAP). ModPath Chat features interviews with authors, opinion leaders and experts on the latest science, technology, and developments in the field of pathology. The monthly podcast series is hosted by Dr. George J. Netto, the Editor-in-Chief of Modern Pathology and the Chair of Pathology at the University of Alabama in Birmingham

Hosted on Acast. See acast.com/privacy for more information.

Latest Episodes:

A Novel Prognostic Score for NSCLC following Neoadjuvant therapy Aug 31, 2021

Show notes

Dr. Sabina Berezowka, from the university of Lausanne Switzerland, discusses with our host her team’s recent study describing a novel “Prognostic Score” for assessing tumor regression following Neaodjuvant therapy in non-small cell lung cancer (NSCLC). The proposed combined prognostic score (PRSC) performed better than pTNM staging and previously published Major Pathologic Response (MPR) approach. Study by Berezowka et al, A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response. Modern Pathology, 34, 1333–1344, 2021. https://www.nature.com/articles/s41379-021-00777-y.

Hosted on Acast. See acast.com/privacy for more information.

DDIT3 Immunohistochemical expression as a diagnostic marker for Myxoid Liposarcoma Aug 18, 2021

Show notes

Dr. Jason Hornick discusses his team recent study finding that a monoclonal antibody directed against the N-terminus of DDIT3 is a highly sensitive and specific for high-grade MLPS. DDIT3 immunostains could replace molecular genetic testing in many cases, although limited labeling may be seen in a range of other tumor types. Study by Hornick et al, Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas. Modern Pathology, 34, 1367–1372, 2021

Hosted on Acast. See acast.com/privacy for more information.

TRIM63 as a biomarker for MiT family RCC Aug 03, 2021

Show notes

In this episode Dr. Rohit Mehra of University of Michigan discusses the utility of TRIM63 as a diagnostic marker to distinguish MiTF-RCC from other renal tumor subtypes with overlapping morphology. In combination with TFE3/TFEB FISH, TRIM63 RNA-ISH assays can improve the accuracy and efficiency of MiTF-RCC diagnosis.

Study by Mehra et al, TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. Modern Pathology, 34, 1596-1607, 2021. https://www.nature.com/articles/s41379-021-00803-z.

Hosted on Acast. See acast.com/privacy for more information.

A MODPATH Chat with Dr. Victor Reuter: The Digital Transformation of Anatomic Pathology Jul 20, 2021

Show notes

Always a visionary, Dr. Reuter was one of the earliest Anatomic Pathologists to embrace and advance the genomic and more recently the digital transformation of our field.

In this episode of Meet The Expert series, Dr. Reuter shares his perspective and vision on the current and future impact of digital pathology

Hosted on Acast. See acast.com/privacy for more information.

Artificial intelligence for advance requesting of IHC in diagnostically uncertain prostate biopsies Jul 06, 2021

Show notes

Dr. Clare Verrill and Andrea Chatrian of Oxford University in England discuss their team’s study on AI for advance ordering of IHC in difficult prostate biopsy. Their elegant work shows that an AI tool making automated IHC request prior to the pathologist read of H&E could create leaner workflow and result in pathologist time savings and shorten overall Turnaround time from accession to final diagnosis. Study by Chatrian et al, Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies. https://www.nature.com/articles/s41379-021-00826-6

Hosted on Acast. See acast.com/privacy for more information.

Synchronous Endometrial and Ovarian Carcinomas: Clonal relationship and directionality of progression. Jun 22, 2021

Show notes

Dr. Britta Weigelt of MSKCC discusses her team’s study on synchronous endometrial (EC) and ovarian carcinomas (OC) in Lynch syndrome and constitutional Mismatch Repair Deficiency Syndrome (CMMRD). Contrary to sporadic synchronous ECs/OCs, which are almost invariably clonally related, ECs/OCs simultaneously involving the uterus and ovary in LS patients may represent two independent primary tumors. Like their sporadic counterparts, a subset of MMR deficiency syndrome-related synchronous ECs/OCs may also originate from a single with the endometrium being the likeliest site of origin.

Study by Weigelt et al, Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. Modern Pathology, 34, 994-1007, 2021. https://www.nature.com/articles/s41379-020-00721-6.

Hosted on Acast. See acast.com/privacy for more information.

Deciphering the Molecular Underpinning of Ulcerative Colitis Associated Colorectal Cancer Jun 08, 2021

Show notes

Dr. Daniela Hirsch, from the Institute of Pathology at the University of Heidelberg in Germany, discusses her findings on the molecular alterations associated with colorectal cancer in the setting of Ulcerative Colitis. Using aCGH, a 48 gene panel and MSI analysis and IHC for TP53, the author and her team revealed high rate of TP53 mutations and gains in chromosome 5p in these predominantly Microsatellite stable tumors. Phylogenic clues about ontogenesis and field effect are discerned from synchronous tumors.

Hosted on Acast. See acast.com/privacy for more information.

Post Neo-adjuvant Chemotherapy Patterns of Residual Breast Cancer May 25, 2021

Show notes

Dr. Stuart Schnitt from Brigham and Women Hospital in Boston discusses his team'srecent findings of variable architectural and cytological patterns of residual disease in breast cancer patients with incomplete pathologic response. The relationship of pattern of residual disease to pre-treatment clinicopathologic parameters and the potential impact on management are discussed.

Study by Pastorello et al, Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. Modern Pathology, 34, 875-882, 2021. https://www.nature.com/articles/s41379-020-00714-5.

Hosted on Acast. See acast.com/privacy for more information.

“Rebranding” Hematopathology Using Twitter: The MD Anderson Experience May 11, 2021

Show notes

In this episode, our guests, Dr. Siba El Hussein and Dr. Sanam Loghavi from the department of hematopathology at MD Anderson Cancer Ctr, discuss their experience on the role of social media in the dissemination of knowledge in hematopathology and establishing networks of collaborators and followers. Editorial by El Hussein et al, Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. Modern Pathology, 34, 854-861, 2021. https://www.nature.com/articles/s41379-020-00715-4

Hosted on Acast. See acast.com/privacy for more information.

USCAP 2021 Long Course: Biomarkers of Response to Check Point Inhibitors - beyond PD-L1 Apr 27, 2021

Show notes

In this fourth and final episode of our special series covering this year’s USCAP Long Course on lung disease, our guest, Dr. Lynette Sholl, chief of pulmonary pathology at the Brigham and Women Hospital discusses her presentation on "Biomarkers of Response to Checkpoint Inhibitors". Dr. Sholl touches upon the potential role of CD8+ T cell count, Multiplex IF based spatial profiling and novel genomic determinants as markers beyond PD-L1.

Hosted on Acast. See acast.com/privacy for more information.

Related Podcasts